NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report

EGFR G724S mutation in exon 18 has been shown to be resistant to both first- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). However, we found a rare mutation of EGFR Ex19del/G724S in two patients with lung cancer who demonstrated a favorable response to...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Huilin Wang, Qitao Yu, Lina Shi, Qinhan Hou, Liang Dan, Chuqiao Liang, Xiaoyu Hong, Yun Zhao, Ruiling Ning
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2022-11-01
Sarja:	Frontiers in Oncology
Aiheet:	EGFR G724S EGFR Ex19del non-small cell lung cancer afatinib chemotherapy
Linkit:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1054593/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!